ASH Annual Meeting and Exposition

The latest news from ASH, including researcher interviews and physician perspective.

Meeting News

ASH announces award recipients

July 15, 2019
Several distinguished leaders in hematology will be honored with awards and special lectures at this year’s ASH Annual Meeting and Exposition…
Meeting NewsVideo

VIDEO: Ibrutinib-rituximab prolongs PFS, OS in chronic lymphocytic leukemia

January 26, 2019
SAN DIEGO — HemOnc Today Editorial Board member Kanti R. Rai, MD, professor of medicine at Zucker School of Medicine at Hofstra/Northwell…
Meeting News

Gemtuzumab ozogamicin well tolerated in multiple regimens for acute myeloid leukemia

January 25, 2019
SAN DIEGO —Gemtuzumab ozogamicin was safe and well tolerated in nearly a dozen different regimens for patients with acute myeloid leukemia or…
Meeting News

DA-EPOCH shows promise in newly diagnosed acute lymphoblastic leukemia

January 24, 2019
SAN DIEGO — Researchers at the ASH Annual Meeting and Exposition reported that dose-adjusted etoposide, prednisone, vincristine…
Meeting NewsVideo

VIDEO: Trials explore optimal treatments, resistance in chronic lymphocytic leukemia

January 18, 2019
SAN DIEGO — In this video, HemOnc Today Editorial Board member John C. Byrd, MD, discusses two late-breaking…
Meeting NewsVideo

VIDEO: Genetic screening rapidly links elderly AML patients to targeted therapy

January 17, 2019
SAN DIEGO — Brittany K. Ragon, MD, a leukemia transplant specialist in the department of hematologic oncology and blood disorders at the…
Meeting News

Triplet combinations with pomalidomide improve response vs. doublet combinations in myeloma

January 5, 2019
SAN DIEGO — Triplet combination regimens containing pomalidomide nearly doubled response rates compared with doublet combination regimens of…
Meeting NewsVideo

VIDEO: Recent trials impact first-line management of chronic lymphocytic leukemia

January 4, 2019
SAN DIEGO — In this video, Jeff Sharman, MD, medical director for hematology research at the U.S. Oncology Network and director of research at…
Meeting News

Venetoclax-rituximab maintains efficacy in chronic lymphocytic leukemia 1-year posttreatment

December 19, 2018
SAN DIEGO — Venetoclax plus rituximab was superior to bendamustine plus rituximab in patients with relapsed or refractory chronic lymphocytic…
Meeting News

Nivolumab safe, feasible with standard induction therapy for acute myeloid leukemia

December 19, 2018
SAN DIEGO — Adding nivolumab to induction therapy with idarubicin and cytarabine appeared to be a viable and safe treatment option for younger…